Ligand validation:3C09

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3C09 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3C09_NAG_D_3281	63%	42%	0.161	0.969	0.68	1.54	-	3	4	0	93%	0.9333
3C09_NAG_D_3282	55%	41%	0.15	0.932	0.68	1.61	-	2	1	0	93%	0.9333
3C09_NAG_A_3281	49%	32%	0.197	0.958	0.85	1.82	1	3	6	0	93%	0.9333
3C09_NAG_A_3282	41%	38%	0.199	0.927	0.74	1.67	-	3	3	0	93%	0.9333
3C09_NAG_A_4201	31%	44%	0.211	0.892	0.63	1.52	-	3	0	0	93%	0.9333
3C09_NAG_A_3891	18%	55%	0.197	0.798	0.6	1.12	-	2	1	0	93%	0.9333
3C09_NAG_A_3371	18%	40%	0.233	0.829	0.55	1.77	-	4	3	0	93%	0.9333
3C09_NAG_D_3891	12%	68%	0.236	0.776	0.57	0.65	-	-	0	0	93%	0.9333
3C09_NAG_D_3371	7%	51%	0.271	0.741	0.5	1.36	-	2	0	0	93%	0.9333
3C09_NAG_A_4202	2%	57%	0.425	0.723	0.56	1.1	-	1	0	0	93%	0.9333
4KRM_NAG_G_605	57%	81%	0.135	0.909	0.34	0.48	-	-	0	0	100%	0.9333
3B2U_NAG_E_3371	45%	52%	0.129	0.858	0.55	1.3	-	3	0	0	100%	0.9333
6B3S_NAG_B_602	36%	58%	0.154	0.848	0.52	1.06	-	2	2	0	100%	0.9333
4KRL_NAG_A_603	20%	78%	0.231	0.837	0.28	0.6	-	-	1	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.